2024-05-24  9:49:17 PM Chg. +0.3800 Volume Bid9:59:58 PM Ask9:59:58 PM Market Capitalization Dividend Y. P/E Ratio
170.5400EUR +0.22% 5
Turnover: 864.5000
-Bid Size: - -Ask Size: - 82.63 bill.EUR - -

Business description

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives. CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology.
 

Management board & Supervisory board

CEO
Paul Perreault
Management board
Alan Wills, Bill Campbell, Bill Mezzanotte, Elizabeth Walker, Greg Boss, John Levy, Mark Hill, Paul McKenzie
Supervisory board
Dr. Brian McNamee, Abbas Hussain, Bruce Brook, Carolyn Hewson, Dr. Megan Clark, Fiona Mead, Marie McDonald, Pascal Soriot, Paul Perreault, Professor Andrew Cuthbertson
 

Company data

Name: CSL Ltd.
Address: Poplar Road 45,Parkville VIC 3052, Australia
Phone: +61-3-9389-1911
Fax: +61-3-9389-1434
E-mail: -
Internet: www.csl.com.au/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 06-30
Free Float: 42.01%
IPO date: 1994-05-30

Investor relations

Name: Mark Dehring
IR phone: +61-3-9389-3407
IR Fax: -
IR e-mail: mark.dehring@csl.com.au